ALP Bio raises €161K from Venture Kick to improve the safety of biologic medicines

Swiss biotech startup ALP Bio has secured €161,000 (CHF 150,000) from Venture Kick to support the commercial development of its platform, which helps drug developers identify immune-related risks earlier in the development process. By combining human immune tissue models with artificial intelligence, the company aims to improve the safety and success rate of next-generation biologic medicines. Biologic drugs, including many therapeutic antibodies, can trigger unwanted immune responses that reduc